Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Cell Medica acquiring Delenex

July 13, 2016 12:47 AM UTC

Cell Medica Ltd. (London, U.K.) is acquiring Delenex Therapeutics AG (Zurich, Switzerland) for undisclosed terms. Cell Medica plans to use Delenex's PENTRA antibody fragment platform to develop next-generation chimeric antigen receptor (CAR)-modified cellular immunotherapies. Delenex's operations will be renamed Cell Medica Switzerland AG and integrated into Cell Medica's global R&D operations. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article